Weifang People’s Hospital, the First Affiliated Hospital of Weifang Medical University, No.151 Guangwen street, Weifang 261000, China
Review Article
Sacubitril/valsartan: a new antihypertensive drug in the future?
Author(s): Guan Xuehao, Zhang Rui, Zhang Guangfang, Wang Jian, Wang Shuguang, Liu Baoshan* and Zhang Aiyuan*
Hypertension is one of the leading epidemic factors of cardiovascular and cerebrovascular disease around the
world. Many researchers have found that Sacubitril/Valsartan, the single angiotensin receptor-neprilysin inhibitor,
played a critical role in lowering hypertension. However, Sacubitril/Valsartan’s indications and usage for hypertension
has not been accepted in the world, except for China. The mechanism of Sacubitril/Valsartan’s antihypertensive
effect is clear, including inhibiting renin-angiotensin system and reducing natriuretic peptides’ degradation.
In this article, we retrieved and reviewed all clinical studies that explored the effect of Sacubitril/Valsartan or its
safety in the treatment of hypertension patients. Most studies concluded that in comparison with traditional
antihypertensive drugs (mainly including angiotensin receptor .. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 